Immunicum AB reveals positive Phase II MERECA clinical trial data
Category: #health  By Pankaj Singh  Date: 2019-08-31
  • share
  • Twitter
  • Facebook
  • LinkedIn

Immunicum AB reveals positive Phase II MERECA clinical trial data

Satisfactory safety profile and the positive number of complete responses by the trials firmly justify the prolonged clinical advancement of ilixadencel as an immune primer in solid tumors.

Immunicum AB (publ), a Swedish biopharmaceutical company, has recently announced positive results from the Phase II MERECA (Metastatic Renal Cell Carcinoma) clinical trials which was focused on evaluating the therapeutic impact of merging Sutent® (sunitinib) with ilixadencel.

As per reports, the most significant outcome of this trial was getting 5 complete responses, defined as no further evidence of disease and eradication of the cancerous tumor, without the additional toxicity created by ilixadencel.

However, the median overall survival has not been achieved yet due to a high rate of overall survival in both study arms. The result also validates the continued clinical development of ilixadencel in other solid tumor indications as well as in kidney cancer.

Speaking on the announcement, Dr. Magnus Lindskog, MERECA investigator and Associate Professor at Uppsala University Hospital, said that being a clinical oncologist who specializes in treating kidney cancer patients, the potential of an immune primer that can uphold the advancement of complete responses in advanced-stage patients with a progressive safety profile and tolerability is very exciting, particularly in an indication where a complete response is rare.

He said that it would be a major step forward for the treatment of kidney cancer if this response rate can be replicated on a bigger pivotal trial.

As for Carlos de Sousa, CEO, Immunicum AB (publ), the company’s main aim from MERECA trials was to study the therapeutic benefit of ilixadencel when merged with a standard treatment regimen. Moreover, the astounding number of complete responses in advanced-stage cancer patients is reassuring and highly supportive of their idea for ilixadencel as primary therapy in modern cancer treatment options.

He further added that the company is eager to conduct the complete investigation of the data and use it to accelerate and refine ilixadencel’s clinical advancements.

Source Credit: https://immunicum.se/investors/press-releases/press/?xml_id=1908171

 



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

RADLogics obtains FDA's approval for AI-based chest X-Ray App
RADLogics obtains FDA's approval for AI-based chest X-Ray App
By Pankaj Singh

RADLogics Inc., a healthcare software company developing AI-powered solutions has reportedly received 510(k) clearance from the US FDA (Food and Drug Administration) for its latest AI-Powered chest X-ray pneumothorax a...

CDE of China NMPA clears I-Mab’s application for lemzoparlimab
CDE of China NMPA clears I-Mab’s application for lemzoparlimab
By Pankaj Singh

Clinical stage biopharmaceutical major, I-Mab, has reportedly announced that it has received the clearance of the Center for Drug Evaluation of the China National Medical Products Administration for its IND application...

Aoyuan Healthy to acquire 55% equity interest in Liantianmei
Aoyuan Healthy to acquire 55% equity interest in Liantianmei
By Pankaj Singh

Aoyuan Healthy Life Group Company Ltd., a renowned commercial property operation service and property management service provider based in China, has reportedly announced that Guangdong Xinyuerong Industrial Investment...